An appeals court has revived a challenge to President Biden’s Medicare drug price reduction program
A constitutional challenge to the Biden administration program enabling Medicare to negotiate lower prices for prescription ...
Zacks.com on MSN3d
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength?
Rhythm Pharmaceuticals, Inc. (RYTM) shares soared 7.4% in the last trading session to close at $53.17. The move was backed by solid volume with far more shares changing hands than in a normal session.
FierceBiotech3d
FDA scraps adcomm for Applied's rare disease drug ahead of November decision
After pushing back the decision date for Applied Therapeutics’ metabolic disorder drug govorestat, the FDA has now decided ...
Team publishes results from clinical trial evaluating cabozantinib in advanced neuroendocrine tumors
The Alliance for Clinical Trials in Oncology today announced that final results will be presented at ESMO 2024 from CABINET ...
Exelixis unveils additional data on Cabometyx for neuroendocrine tumors
Exelixis releases positive phase 3 data on Cabometyx for pancreatic and extra-pancreatic neuroendocrine tumors, seeking ...
Health.com5d
Turmeric, Ashwagandha, and 4 Other Herbal Supplements That Could Be Damaging Your Liver
The study, published last month in JAMA Network Open, found that the U.S. is seeing an uptick in drug-induced liver injury ...
Medexus Provides Update on Treosulfan NDA Review Process and Extended PDUFA Goal Date
Medexus Pharmaceuticals Inc. Toronto, Ontario and Chicago, Illinois–(Newsfile Corp. – September 16, 2024) – Medexus ...
Business Wire7d
Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic ...
Exelixis intends to submit a supplemental New Drug Application with the U.S. Food and Drug Administration for cabozantinib in combination with atezolizumab for mCRPC later this year. About CONTACT-02 ...
Business Wire8d
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC ...
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today a ...
MedPage Today8d
Approved Liver Disease Drug Has No Clinical Benefit, FDA Panel Says
Obeticholic acid had been awarded accelerated approval by the FDA in May 2016 as a second-line treatment for PBC patients not ...